Bomedemstat

Phase 3Small molecule

Merck & Co.

Bomedemstat is one of 140 small molecule programs targeting Myelofibrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

139

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyelofibrosisUnknown status

Safety and EfficacyRecruiting

Polycythemia VeraCompleted

Acute Myeloid LeukemiaRecruiting

Essential ThrombocythemiaActive, not recruiting

MyelofibrosisPhase 2

Unknown status

Safety and EfficacyPhase 3

Recruiting

Polycythemia VeraPhase 2

Completed

Acute Myeloid LeukemiaPhase 1

Recruiting

Essential ThrombocythemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

34 2

Xospata

Astellas

Phase 3

24 3

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 4

Vepesid

AAvyxa

Phase 3

52 5

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 7

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 8

Cellcept

Roche

Phase 3

10 9

Busulfex

Trexall

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Acute Myeloid Leukemia

NCT05597306

Q1 2028

Phase 3Active, not recruiting

Essential Thrombocythemia

NCT06456346

Q3 2028

Phase 3Active, not recruiting

Essential Thrombocythemia

NCT06079879

Q4 2029

Phase 2Not yet recruiting

Myelofibrosis

NCT07424950

Clinical

Trials by Indication[1]

Myelofibrosis3 trials

Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

Not yet recruiting·—·Phase 2·NCT07424950·40 enrolled

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT03136185·90 enrolled

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Unknown status·TThe University of Hong Kong·Phase 2·NCT05569538·40 enrolled

Essential Thrombocythemia3 trials

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04254978·73 enrolled

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06456346·300 enrolled

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06079879·340 enrolled

Polycythemia Vera2 trials

A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05558696·20 enrolled

A Phase 2/3, Randomized, Open-label, Active-comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) Versus Best Available Therapy in Participants With Polycythemia Vera Who Have an Inadequate Response to or Are Intolerant to Hydroxyurea

Not yet recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07722611·380 enrolled

Moderate Hepatic Impairment1 trial

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT07049939·9 enrolled

Interaction1 trial

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06596668·16 enrolled

5 more indications

Myeloproliferative Neoplasms1 trial

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05223920·81 enrolled

Safety and Efficacy1 trial

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06351631·400 enrolled

Myeloid Malignancies1 trial

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT02842827·45 enrolled

Small Cell Lung Cancer1 trial

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Terminated·UUniversity of Washington·Phase 1/2·NCT05191797·3 enrolled

Acute Myeloid Leukemia1 trial

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting·—·Phase 1·NCT05597306·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Bomedemstat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bomedemstat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bomedemstat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Bomedemstat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q3 2028

Q4 2029

Trials by Indication[1]

Myelofibrosis3 trials

Essential Thrombocythemia3 trials

Polycythemia Vera2 trials

Moderate Hepatic Impairment1 trial

Interaction1 trial

Myeloproliferative Neoplasms1 trial

Safety and Efficacy1 trial

Myeloid Malignancies1 trial

Small Cell Lung Cancer1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News